NEW YORK (GenomeWeb News) – Japan’s Yamatake has licensed Oxford Gene Technology’s oligonucleotide microarray patents to make and sell its own arrays, OGT said today.
 
Yamatake will manufacture gemkey microarrays using in situ synthesis. Yamatake is the only Japanese company using in situ synthesis, said Michael Bennett, OGT’s vice president of licensing.
 
The company will market the microarrays through its distributor, Sigma-Aldrich Japan.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.

Jun
21
Sponsored by
Roche

This webinar will provide a detailed look at how a genomics lab implemented next-generation sequencing (NGS) liquid biopsy assays into its in-house clinical research program.